Concepedia

Michael A. Batey

MA

Statistics

Publications

10

Citations

1.7K

H-Index

10

Active since

1998

Affiliations

Newcastle University(Current)

GW Pharmaceuticals (United Kingdom)

Michael A. Batey is an author at Newcastle University specializing in oncology, medicine, and pharmacology.

Publications per year

1998–2014

10

Publications

10

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Christopher Calabrese, Robert J. Almassy, Stephen Barton et al. · JNCI Journal of the National Cancer Institute · 2004 · 485 citations · Full text

, , +15

Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441

Yan Zhao, Huw D. Thomas, Michael A. Batey et al. · Cancer Research · 2006 · 447 citations · Full text

, , +16

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Huw D. Thomas, Christopher Calabrese, Michael A. Batey et al. · Molecular Cancer Therapeutics · 2007 · 302 citations

, , +15

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, <i>In Vitro</i> and <i>In Vivo</i> in p53 Functional and Dysfunctional Models of Human Cancer

Michael A. Batey, Yan Zhao, Suzanne Kyle et al. · Molecular Cancer Therapeutics · 2013 · 158 citations · Full text

, , +17

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

Joanne M. Munck, Michael A. Batey, Yan Zhao et al. · Molecular Cancer Therapeutics · 2012 · 131 citations · Full text

, , +11

1–5 of 10